1.1700
-0.0290
(-2.42%)
At close: April 17 at 5:12:31 PM GMT+2
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
3,925
3,925
6,225
26,909
14,267
Cost of Revenue
4,267
4,267
6,119
6,339
5,745
Gross Profit
-342
-342
106
20,570
8,522
Operating Expense
94,363
94,363
89,029
95,176
99,927
Operating Income
-94,705
-94,705
-88,923
-74,606
-91,405
Net Non Operating Interest Income Expense
1,412
1,412
2,769
-6,641
-18,584
Other Income Expense
-34,735
-34,735
-10,208
1,281
-978
Pretax Income
-128,028
-128,028
-96,362
-79,966
-110,967
Tax Provision
-1,793
-1,793
-458
-189
-160
Net Income Common Stockholders
-126,235
-126,235
-95,904
28,317
-92,166
Diluted NI Available to Com Stockholders
-126,235
-126,235
-95,904
28,317
-92,166
Basic EPS
-0.47
-0.47
-0.39
0.14
-0.47
Diluted EPS
-0.47
-0.47
-0.39
0.14
-0.47
Basic Average Shares
267,727.4260
267,727.4260
244,536.2210
200,360.8210
197,759.9000
Diluted Average Shares
267,727.4260
267,727.4260
244,536.2210
200,360.8210
197,759.9000
Total Operating Income as Reported
-135,029
-135,029
-99,758
-75,726
-91,948
Total Expenses
98,630
98,630
95,148
101,515
105,672
Net Income from Continuing & Discontinued Operation
-126,235
-126,235
-95,904
28,317
-92,166
Normalized Income
-86,475.7275
-86,475.7275
-85,120.4978
-78,659.6471
-110,264.7829
Interest Income
1,418
1,418
3,237
133
171
Interest Expense
6
6
468
6,774
18,755
Net Interest Income
1,412
1,412
2,769
-6,641
-18,584
EBIT
-128,022
-128,022
-95,894
-73,192
-92,212
EBITDA
-123,496
-123,496
-89,226
-62,427
-78,451
Reconciled Cost of Revenue
4,267
4,267
6,119
6,339
5,745
Reconciled Depreciation
4,526
4,526
6,668
10,765
13,761
Net Income from Continuing Operation Net Minority Interest
-126,235
-126,235
-95,904
-79,777
-110,807
Total Unusual Items Excluding Goodwill
-40,324
-40,324
-10,835
-1,120
-543
Total Unusual Items
-40,324
-40,324
-10,835
-1,120
-543
Normalized EBITDA
-83,172
-83,172
-78,391
-61,307
-77,908
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-564.7275
-564.7275
-51.4978
-2.6471
-0.7829
12/31/2021 - 12/2/2013
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
4QK.SG Codexis Inc
1.8460
+1.65%
4QK.F Codexis, Inc.
1.8460
+0.65%
ITH.F Nektar Therapeutics
0.5740
+5.03%
LEXXW Lexaria Bioscience Corp.
0.3400
-8.11%
CMPX Compass Therapeutics, Inc.
1.7500
+2.94%
LYRA Lyra Therapeutics, Inc.
0.0865
-5.98%
ALEC Alector, Inc.
0.9201
-5.95%
FGEN FibroGen, Inc.
0.2863
+3.13%
SLDB Solid Biosciences Inc.
2.5500
+1.19%
ITRM Iterum Therapeutics plc
1.0800
+2.86%